MAY 09, 2017 08:00 AM PDT

WEBINAR: Deafness in the Genomic Era: Discoveries, Challenges and Opportunities

SPONSORED BY: Agilent
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Research Scientist/Team Leader, University of Iowa
    Biography
      Hela is a Research Scientist at the Molecular Otolaryngology and Renal Research Laboratories (MORL) at the University of Iowa, USA. She received her Bachelor of Science and her Master of Science degrees (Biological engineering) at the University of Sfax in Tunisia and her Ph.D. degree in Human Molecular Genetics at the University of Sfax conjointly with the University of Iowa. After completing a postdoctoral fellowship at the MORL at the University of Iowa, Hela was appointed as Assistant Professor at the Pasteur Institute of Tunis in Tunisia. After working there for two years on characterizing the genetic etiology of orphan diseases in the Tunisian population, she returned back to the USA where she is currently leading the hearing research team at the MORL. Her current research program is focused on the discovery of novel genes, genetic modifiers and non-coding regulatory elements involved in hereditary deafness as well as the investigation of genetic contributions to age- and noise-induced hearing loss. She is in charge of developing next-generation sequencing platforms and gene panels along with creating solutions to improve interpretation and clinical correlation of genomic variants. She aims to translate novel knowledge acquired through research into clinical diagnostics.

    Abstract:

    DATE: May 9, 2017
    TIME: 8:00am PT, 11:00am ET

    Hearing loss is the most common sensory defect in humans. It affects 360 million people worldwide and by 2020, that number is predicted to reach 1 billion. The genetic and allelic heterogeneity associated with hereditary deafness are well established. Over 90 genes and 2000 mutations are causally linked to non-syndromic hearing loss (NSHL), which exhibits a wide spectrum of phenotypic diversity in onset, severity, progression and audioprofiles. Developing a comprehensive approach to tackle this extraordinary heterogeneity has become the cornerstone for genetic analysis. Capitalizing on technological advances, we have developed OtoSCOPE®, a next-generation sequencing platform that simultaneously screens 152 genes known to cause NSHL as well as common syndromic forms.

    We sought to make this analysis widely available as an inexpensive and highly informative genetic analysis that would assist in the evaluation of persons with hearing impairment. To achieve this goal, we developed and optimized a customized pipeline to identify, annotate, categorize and prioritize sequence variants including SNVs, indels and importantly, copy number variations (CNVs). We also implemented a multidisciplinary approach that integrates a set of tools to determine the clinical significance of genetic variations. For example, we have created the Deafness Variation Database (DVD), an open-access database of all variants in all genes implicated in NSHL, and AudioGene, a machine-learning algorithm that analyzes audiometric data to predict likely genetic causes of deafness. AudioGene can also identify audiometric outliers at each deafness locus.

    During this webinar, we will present the challenges we have faced and the solutions we have created to overcome them. We will discuss the knowledge we have acquired that has advanced our understanding of the molecular genetics of deafness. We will also showcase specific case studies to highlight the genetic and phenotypic complexities of hereditary deafness.

    Learning objectives

    • Targeted gene panels for deafness offer an efficient, cost-effective, customizable, high-throughput and high-depth sequencing approach to detect rare variants and CNVs, and to shed light on the hidden complexities of hereditary deafness
    • The massive depth of coverage associated with targeted gene panels facilitates the detection of CNVs, which make a significant contribution to NSHL. Their detection must be integrated in all NGS pipelines for deafness.   
    • Most identified deafness variants are novel or rare, and of unknown significance, making their interpretation challenging. The integration of audiometric and genetic data facilitates meeting this challenge.
       

    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    JUN 26, 2018 06:00 AM PDT
    C.E. CREDITS
    JUN 26, 2018 06:00 AM PDT
    Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    Loading Comments...